Table Shells

Attachment 2 Table Shells.docx

NIEHS DERT Extramural Grantee Data Collection

Table Shells

OMB: 0925-0657

Document [docx]
Download: docx | pdf

Attachment 2

Table Shells for Analysis

Table 1. Percentage of Investigators receiving each type of funding in the past 10 years and throughout career and primary sources of funding for same time periods

Funding Source

Percentage of Investigators receiving funding


Career Last 10 years

Percentage of Investigators receiving primary funding


Career Last 10 years

NIEHS





NHLBI





NIAID





NICHD





Other NIH





CDC





AHRQ





FDA





EPA





HUD





NSF





Other US government (not listed above)





Foundations





Industry





University discretionary/ start-up funds





Local, state or regional government





Other







Table 2. Percentage of Investigators receiving specific types of NIH-funding for research

Type of Funding

Percentage of Investigators

Research (e.g., R01, R03, R21)


Program/Center (e.g., M, P and U awards)


Career Development Individual (e.g., K awards; R23, R29)


Fellowships (e.g., F awards)


Institutional Training (e.g., T32)


Technology Development (e.g., SBIR, STTR; R41-44, N43-44, U43-44)




Table 3. Percentage of researchers engaged in basic and applied sciences related to the selected science portfolio by field

Field of Research

Percentage of Investigators

Basic Sciences

Biochemistry

Biophysics

Botany

Cellular biology

Ecology

Environmental Sciences

Epigenetics

Genetics

Immunology

Medicine

Microbiology

Molecular biology

Physiology

Toxicology

Other please specify________



Applied Sciences

Clinical Research

Public Health Research

Health Services Research

Intervention Research

Program or Policy Research

Technology Innovation

Translational Research

Other please specify________





Table 4. Age distribution of investigators

Age Category

Percentage of Investigators

<30


30-39


40-49


50-59


60+



Table 5. Percentage of investigators by degrees awarded

Degree

Percentage of Investigators

AB, BA, BS, BSc


MA, MS, MHS, MPH, MPA, MED, MSIH


PhD, Sc.D, DSc


MD


Other clinical degree (e.g. DO, DDS, MBBS, RN)


None




Table 6. Distribution of year of highest degree

Year

Percentage of Investigators

1976-1980


1981-1985


1986-1990


1991-1995


1996-2000


2001-2005


2006-




Table 7. Number/Percentage of Research Outputs Produced by Investigators


Research Output

Number of Investigators

Percentage of Projects

Biological Materials



Biological material or application identified or developed as a result of the research study.



Databases,

Software,

Algorithms



Database resulting from the research study.




Software resulting from the research study.




Algorithm resulting from the research study.



License Agreements



License agreement executed for intellectual property generated by the research study.



Measurement Instruments



Measurement instrument developed by the research study.



Research Data (public or restricted)


Research data generated by the research study.



Economic Outcomes


Research study findings result in a cost-effective intervention for a disease, condition, or disorder.





Research study findings result in enhancement of existing resources and expertise.




Research study findings result in increased performance, quality, and consistency in the delivery of health care services.



Health Care Outcomes


Research study findings result in clinically effective approach in the management and treatment of a disease, disorder or condition.



Quality of Life


Research study findings leads to enhancement of well-being among community members.





Table 8. Number/Percentage of Knowledge Transfer Outputs Achieved by Investigators


Knowledge Transfer Output

Number of Investigators

Percentage of Projects

Alternative/

Informal Dissemination



Research study is referred to or cited in a blog, tweet, wiki or other alternative mode of dissemination.




Research study is cited in a presentation, speech or teaching materials.



Biological Materials



Subsequent use of a particular biological material or application of the material generated by the research study in a bench study (basic science) or clinical trial study.




Clinical data generated in support of marketing a biological material (BLA) generated by the research study.



Clinical Guidelines


The clinical guideline refers to the research study or recommends the study for background readings.



Curriculum Guidelines



The curriculum guideline refers to the research study or recommends the study for background readings.



License Agreements



License agreement granted for use of intellectual property generated by the research study.



Mass Media


Mass media publication refers to the research study.



Material Transfer Agreements (MTA)


MTA executed for transfer of tangible property generated by the research study.



Medical Devices



Clinical trial study testing of a medical device generated by the research study.




Clinical data generated in support of marketing a medical device (510(k); Investigational Device Exemption, IDE; or Premarket Approval, PMA) generated by the research study.



Meta-Analyses


Research study cited in a meta-analysis.



Pharmaceutical Preparations



Subsequent use of a drug generated by the research study in a bench study (basic science) or clinical trial study.




Clinical data generated in support of marketing a drug (Investigational New Drug Application, IND; New Drug Application, NDA; Abbreviated New Drug Application, ANDA; or 505(b)(2)) generated by the research study.



Ancillary Research Studies


Ancillary research study generated as a result of the research study.



New Research Studies



New research study generated as a result of the research study.



Subject Headings/

Thesauri

New subject heading or thesauri term or phrase resulting or related to the research study is applied.





Table 9. Career Development Outputs



Table 10. Training Outputs


Table 11. Percentage of investigators that have disseminated research by the following mechanisms


Dissemination mechanism

Percentage of investigators

Published in peer-reviewed journals


Presented at scientific conferences


Participated in grantee meetings


Developed and disseminated curricula


Developed and disseminated interventions


Developed and disseminated research tools and methods


Participated in the development of clinical guidelines for the treatment of asthma


Participated in workshops or trainings disseminating your research


Provided scientific testimony and briefings to legislators


Developed and published websites


Presented research in community forums


Developed fact sheets and pamphlets


Provided information for press releases





Table 12. Nature of investigator personal engagement by type of engagement


Percentage of Investigators

Group

Share information

Conduct joint projects or activities

Serve on boards or advisory panels

Provide formal testimony

Serve as employee or consultant

No interaction

Other researchers







University administration / program directors







Local, regional or national health officials







Environmental regulators







Food and drug regulators







Legislators and staffers







Business and industry representatives







Housing and urban development agencies







Advocacy groups







Community groups









Table 13. Percentage of Investigators who have applied for patents and commercialized innovation

IP Action

Percentage of Investigators

Patent application


Patent


Nature of patent

New drug

New use of drug

Medical product or device

Environmental controls and services

New process or procedure

New research method

New gene


Commercialization of Patent


License Patent


Started spin-off or new company




Table 14. Percentage of investigators who received patents and received support from federal agencies, by agency

Agency

Percentage of Investigators

NIEHS


NHLBI


NIAID


NICHD


Other NIH


CDC


AHRQ


FDA


EPA


HUD


NSF


Other US government (not listed above)




Table 15. Community Partnership Outputs (Response options will be created based on feedback to open-ended questions).


Community Partnership Output

Number of Investigators

Percentage of Projects




















Table 16. Percentage of investigators who believe research has had or may have future impacts in the next 10 years by impact area

Impact Area

Percentage of Investigators


Current Impact

Future Potential Impact

greater understanding of the selected science portfolio’s disease mechanisms



greater understanding of individual, social, and environmental factors associated with the selected science portfolio



improved environmental measurement techniques



increased evidence regarding effective interventions



improved environmental control techniques



to changes in curriculum for clinical/public health students



changes in curriculum for K-12 or families



changes in business practices regarding the selected science portfolio



changes in environmental standards or regulations for the selected science portfolio



changes in public health/environmental legislation related to asthma



changes in clinical guidelines for the selected science portfolio



changes in clinical practice relevant to the selected science portfolio



changes in public knowledge and practices related to the selected science portfolio prevention and control



increased public advocacy for the selected science portfolio prevention and control




Table 12. Percentage of investigators who believe research has had impacts by impact area and by NIEHS funding status

Impact Area

Percentage of Investigators


No NIEHS funding

NIEHS funding

NIEHS funding primary

greater understanding of the selected science portfolio disease mechanisms




greater understanding of individual, social, and environmental factors associated with the selected science portfolio




improved environmental measurement techniques




increased evidence regarding effective interventions




improved environmental control techniques




changes in curriculum for clinical/public health students




changes in curriculum for K-12 or families




changes in business practices regarding the selected science portfolio




changes in environmental standards or regulations for the selected science portfolio




changes in public health/environmental legislation related to the selected science portfolio




changes in clinical guidelines for the selected science portfolio




changes in clinical practice relevant to the selected science portfolio




changes in public knowledge and practices related to the selected science portfolio prevention and control




increased public advocacy for the selected science portfolio prevention and control







File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File TitleAttachment 5
AuthorBattelle
File Modified0000-00-00
File Created2021-01-24

© 2024 OMB.report | Privacy Policy